US FDA And Sponsors Resolve Disclosure Issues On Complex Trial Design Pilot Projects
Executive Summary
Agency officials can now discuss the ideas that have been accepted, though not in great detail.
You may also be interested in...
PDUFA VII: Human Factors Review, Finance Flexibility, REMS, And Manufacturing Get Attention
User fee reauthorization negotiators from US FDA and industry divide into subgroups to tackle specific issues before moving to the broader agreement.
How US FDA And Industry Are Looking To Navigate New Supply Chain Data Reporting Requirements
FDA Commissioner Hahn says industry needs to work with the agency to establish a link to more detailed supply chain information.
PDUFA VII: Will Gene Therapy's Rise Influence Talks?
The Center for Biologics Evaluation and Research may need more fee revenue to add employees to handle the increasing cell and gene therapy workload.